Stay updated with breaking news from Alpine Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jumps for Big Tech stocks helped U.S. stock indexes claw back much of their slide from the day before, when worries that interest rates may stay high for a while
These are some of the stocks posting the largest moves in midday trading.
Currently, the Alpine drug is set to enter a Phase 3 clinical trial by the end of the year and studies of its application in renal indications and autoimmune cytopenias are ongoing.
:max_bytes(150000):strip_icc()/VRTXChart-16089af1405e4288a0e607c8ad87c01a.GIF)
Vertex shares slipped in extended trading Wednesday after the company announced it had agreed to acquire Alpine Immune Sciences for $4.9 billion. Monitor this important chart level.
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth potential, with Alpine's lead molecule poised to add over $5 billion in sales.